NCT02107222撤回不适用
A Multicenter Randomized Control Trial (RCT) to Determine Safety and Efficacy of PALP™ for ECCO2-R in Conjunction With Liberation From Mechanical Ventilation (MV) Compared to MV Alone in COPD Exacerbation and Respiratory Failure
Maquet Cardiopulmonary GmbH2 个研究点 分布在 1 个国家开始时间: 2014年4月8日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 发起方
- 试验地点
- 2
- 主要终点
- Difference in time of mechanical ventilation
研究概览
简要总结
A Multicenter, Randomized, Controlled Trial to Determine Safety and Efficacy of Pump Assisted Lung Protection (PALP™) for Low Flow Carbon Dioxide (CO2) Removal in Conjunction with Liberation from Mechanical Ventilation Compared to Mechanical Ventilation Alone in Patients with COPD Exacerbation and Respiratory Failure
详细描述
Primary Study Objectives
• To evaluate the clinical effect of PALP™ in reducing the time on invasive ventilation in patients with an exacerbation of COPD requiring invasive mechanical ventilation.
Secondary Study Objectives
- To evaluate the safety and tolerability of PALP™ in patients with an exacerbation of COPD requiring invasive mechanical ventilation.
- To determine if rates of adverse events (AEs) are reduced in patients who receive PALP™ and invasive mechanical ventilation vs invasive mechanical ventilation alone.
- To determine mortality rates in patients who receive PALP™ and invasive mechanical ventilation vs invasive mechanical ventilation alone.
- To determine if PALP™ will effectively reduce the number of subsequent acute decompensations requiring hospital admission for ventilatory support (invasive or noninvasive).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, and ≥40 years of age
- •Known history of COPD
- •Currently experiencing an exacerbation of COPD
- •P/F ratio >150 mmHg
- •Currently endotracheally intubated and requiring invasive mechanical ventilation (must have been on invasive mechanical ventilation for 24-48 hours)
- •Able to tolerate large bore intravenous (IV) cannulation required for proper operation of study device
- •For female patients of child-bearing potential, a negative urine or serum pregnancy test at screening; all female patients will be considered of child-bearing potential unless they are post menopausal for at least 1 year or have been surgically sterilized (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy)
- •Written informed consent obtained according to local regulations; or, if unable to provide written informed consent due to incapacitation, a legally authorized representative is able to provide written informed consent on behalf of the patient
排除标准
- •Any end-stage medical conditions with expected survival <6 months
- •Tracheostomy
- •Unable to provide central venous access
- •Acute brain injury
- •Any legally authorized document(s) that may restrict aggressive medical management such as "Do Not Resuscitate," "Do Not Intubate," etc.
- •Risk of bleeding or clotting such as:
- •Known bleeding diathesis or abnormal clotting
- •Recent or current use of medications known to increase risk of bleeding
- •Screening platelet count of <75,000/mm3 or international normalized ratio (INR) >1.5 or activated partial thromboplastin time (aPTT) >1.5 times the upper limit of normal (ULN) range for their respective laboratory values
- •Any recognized contra indications to systemic anticoagulation therapy or use of heparin
- •Body mass index (BMI) >35
- •Any form of chronic hyperventilation not related to COPD
- •Hemodynamic instability or requiring significant vasopressor support
- •Cardiogenic or noncardiogenic pulmonary edema as the primary reason for respiratory failure
- •High risk cardiac conditions
- •Oxygen tension in arterial blood (PaO2) <50 mmHg via arterial blood gas (ABG) or any condition in which hypoxemia is a significant component of the respiratory failure
- •Any other medical cause for acute respiratory failure not directly related to a COPD exacerbation
- •Use of or treatment with an investigational drug, therapy, or device within 1 month (30 days) of baseline
- •Female patients who are pregnant or breastfeeding
- •Patients who are immuno-compromised
- •Current active malignancy or history of malignancy within the past 5 years
- •Patients in chronic dialysis
- •Patients requiring extra-corporeal life support (ECLS) as a bridge to transplant
- •Patients who, in the opinion of the investigator, would not be able to comply with the requirements of the study
结局指标
主要结局
Difference in time of mechanical ventilation
时间窗: 720 hours
• To evaluate the clinical effect of PALP™ in reducing the time on invasive ventilation in patients with an exacerbation of COPD requiring invasive mechanical ventilation.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Safety and Efficacy Study of Posaconazole vs. Fluconazole for Prevention of Invasive Fungal Infection (P05387 AM1)(COMPLETED)LeukopeniaNCT00811928Merck Sharp & Dohme LLC252
Unknown
不适用
The Puncturable Atrial Septal Defect Occluder Trial (the PASSER Trial)Atrial Septal DefectNCT05371366Shanghai Zhongshan Hospital128
Unknown
不适用
Antigenic and Antibody Detection of CandidaTo Evaluate the Diagnostic Value of Candida Antigen Antibody Detection for Candida InfectionNCT03766932Chinese PLA General Hospital500
尚未招募
2 期
The Efficacy of Combination of Traditional Tibetan and Remote Ischemic Conditioning on High Altitude PolycythemiaHigh Altitude PolycythemiaNCT06082583Capital Medical University300
已完成
1 期
Randomized Comparison of the RePneu Lung Volume Reduction Coil (LVRC) to Standard of Care for the Treatment of Emphysema (RESET Study)EmphysemaNCT01334307Boston Scientific Corporation47